A nonprofit research and development organization has launched a new program to adapt HIV/AIDS medications for safer, more effective pediatric use.
The Drugs for Neglected Diseases initiative (DNDi), which is based in Geneva, Switzerland, announced the new effort in July. The program will build on the DNDi's work in developing and delivering new treatments for such neglected diseases as sleeping sickness, leishmaniasis, and Chagas disease.